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EDITORIAL COMMENTARYManagement of residual lesions following surgery for congenital
heart defects: Evidence versus judgmentChristian Pizarro, MDSee related article on pages 2540-7.As rates of survival following surgery for congenital heart
disease continue to improve, outcome metrics are shifting
from survival to measures of morbidity, quality, and cost.
The presence of residual lesions following intervention
can have a significant influence on these metrics. Therefore,
attention is being drawn to evidence–based data that could
inform the decision making regarding the need and timing
of reintervention to address residual lesions and optimize
outcomes.
The work by Nathan and colleagues1 provides a
comprehensive analysis of a large cohort of patients un-
dergoing surgery for congenital heart disease in an
attempt to elucidate the effect of residual lesions and
the timing of reintervention on postoperative length of
stay, adverse events, and cost. Although at first glance
the answer might seem obvious, the decision about repair-
ing a residual lesion and its timing is commonly informed
by many factors, including some we have no way to mea-
sure. In my view, the work by Nathan and colleagues1 rep-
resents an important initial step to acquire the evidence
necessary to inform these complex decisions, and allows
us a better understanding of the effect of the timing of
reintervention. However a number of factors—including
patient features, criteria for reintervention, and the
complexity of the procedure—play an important role in
this decision and should not be underestimated. Is it the
same to address moderate residual regurgitation after
mitral valve repair in a school-aged child as it is to
perform an intraoperative revision of a distal arch recon-
struction for a 15 mm Hg gradient in a newborn infant af-
ter repair of a Taussig-Bing anomaly? Whereas we may
have consensus on the first, different opinions may exist
on the latter and we clearly need data to help us reach
the best answer in each case. Many scenarios arise where
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sions must be pursued immediately. Residual lesions
tend to occur in the youngest and smallest patients with
the most complex lesions. These individuals pose the
most important challenges when it comes to imaging, ac-
cess, and the technical aspects of surgery, particularly
intracardiac repair. The stakes are high and the margin
for error is slim. Consider the side effects and potential
morbidity and mortality associated with prolonged and
repeated operations, including extended duration of car-
diopulmonary bypass, including myocardial ischemia.
Therefore, deciding what reintervention and when to
perform it is of paramount importance. In the youngest
patients good data to help us discern between those resid-
ual lesions that should be addressed and those that could
be tolerated would be most helpful. In the meantime, we
must rely on the judgment of accomplished cardiac sur-
geons who possess substantial experience operating on
neonates in achieving a favorable benefit-harm ratio.
In the cohort analyzed by Nathan and colleagues,1
patients undergoing intraoperative reintervention (IO)
were older, had simpler lesions, and had a high predomi-
nance of valve surgery at index operation. Not surprising
is the fact that IO achieved similar outcomes to those in
patients who did not have residual lesions and were
clearly superior to those undergoing postoperative inter-
vention (PO). In contrast, patients younger than age 1
year—most of whom underwent nonvalve-related proce-
dure at the index operation—exhibited increased mortal-
ity when they required IO revision, illustrating that IO
carries potential risks. In fact, subgroup analysis of pa-
tients with major residual lesions who underwent PO re-
intervention showed that these patients were younger,
had a higher proportion of prematurity, had more complex
conditions, and a worse outcome. These facts illustrate the
higher complexity of those individuals who underwent PO
reintervention, for which the matched analysis could not
entirely control.
Despite these limitations, the work by Nathan and col-
leagues1 is important and keeps us focused on the need
for evidence to determine the effect of residual lesions
following surgery for congenital heart defects and to define
which ones should be addressed and when. I agree that
intraoperative assessment of the adequacy of repair is
important, generating data about what to do with this infor-
mation is the true objective.
We all strive for a perfect surgical intervention, but not
infrequently we face residual issues. For the time being, itgery c December 2014
Pizarro Editorial Commentaryis our judgment and experience that help us to walk the line
between solving these issues and making matters worse. I
look forward to the day when good evidence will facilitate
these decisions.The Journal of Thoracic and CarReference
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